According to the company, the expansion into the US will ensure that appropriate resources are available to support its numerous planned clinical programs as well as subsequent US product launches.
Members of Cytochroma’s current management team to be based in the Bannockburn office include Joel Melnick, vice president of clinical and regulatory Affairs and Eric Messner, vice president of commercial operations. The company will retain and continue growing its existing corporate headquarters in Markham.
Charles Bishop, president and CEO of Cytochroma, said: “This is an ideal time for Cytochroma to establish US operations, as we move our lead programs into mid- to late-stage clinical trials and execute plans to develop our commercial infrastructure.”